CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT improves staging and alters management in marginal zone lymphoma: a prospectively recruited head-to-head study with [18F]FDG
European Journal of Nuclear Medicine and Molecular Imaging · 2026-09 · 53 (11) · 6375-6385
DOI: 10.1007/s00259-026-07978-0 ↗Kurz gefasst
Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 03.06.2026. Verfasst von Zitong Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Receptors, CXCR4, Coordination Complexes, Peptides, Cyclic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, China Postdoctoral Science Foundation, the Post Doctor Research Fund of West China Hospital, Sichuan University.
Abstract (Originalsprache)
BACKGROUND: Marginal zone lymphoma (MZL) exhibits substantial clinical heterogeneity, necessitating accurate whole-body tumor burden assessment and early risk stratification. However, conventional [18F]FDG PET/CT is limited in both anatomical staging and in vivo biological characterization. This prospectively recruiting study conducted a head-to-head comparison of the CXCR4-targeted tracer [68Ga]Ga-PentixaFor and [18F]FDG in treatment-naïve patients to evaluate their complementary value in improving staging accuracy and their association with early treatment response. METHODS: Forty-one treatment-naïve MZL patients prospectively underwent dual-tracer PET/CT prior to therapy. Lesion detection rates, stage migration, and management modifications were systematically assessed. The prognostic value of baseline imaging parameters for interim treatment response was also analyzed. RESULTS: [68Ga]Ga-PentixaFor demonstrated significantly higher lesion detection rates than [18F]FDG, particularly for gastric (72.0% vs. 40.0%) and nodal involvement (97.4% vs. 39.7%), with a superior target-to-background ratio (median TBRliver: 5.55 vs. 2.42, p 7.96) was associated with lower complete remission (CR) rates. Notably, dual-tracer phenotyping further demonstrated decreasing CR rates across double-negative, single-positive, and double-positive groups (100%, 61.5%, and 36.4%, respectively). CONCLUSION: [68Ga]Ga-PentixaFor PET/CT significantly outperforms [18F]FDG in initial staging of MZL and has a substantial impact on clinical management. Importantly, dual-tracer imaging shows potential as a novel, non-invasive biomarker for in vivo phenotypic characterization, which is associated with early therapeutic outcomes and the identification of high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China.
- Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China. zouliqun1971@163.com.
- Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China. jiangming79@wchscu.cn.
- Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China. jiangc_nju@163.com.
- Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China. rongtiannuclear@126.com.
ORCID-Profile: Rong Tian
Förderung
- the National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- the Post Doctor Research Fund of West China Hospital, Sichuan University
- Residency Research Foundation of West China Hospital, Sichuan University
Zitieren
APA
Zhang, Z., Hu, H., Li, X., Xiang, Y., Gao, L., Liu, Y., Huang, H., Zou, L., Jiang, M., Jiang, C., & Tian, R. (2026). CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT improves staging and alters management in marginal zone lymphoma: a prospectively recruited head-to-head study with [18F]FDG. European Journal of Nuclear Medicine and Molecular Imaging, 53(11), 6375-6385. https://doi.org/10.1007/s00259-026-07978-0
Vancouver
Zhang Z, Hu H, Li X, Xiang Y, Gao L, Liu Y, et al. CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT improves staging and alters management in marginal zone lymphoma: a prospectively recruited head-to-head study with [18F]FDG. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(11):6375-6385. doi:10.1007/s00259-026-07978-0
BibTeX
@article{Zhang2026,
author = {Zhang, Zitong and Hu, Haoyuan and Li, Xin and Xiang, Yongzhao and Gao, Limin and Liu, Yunyi and Huang, Hexiao and Zou, Liqun and Jiang, Ming and Jiang, Chong and Tian, Rong},
title = {CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT improves staging and alters management in marginal zone lymphoma: a prospectively recruited head-to-head study with [18F]FDG},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {11},
pages = {6375--6385},
doi = {10.1007/s00259-026-07978-0}
}
EUVIMED